The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations ...

Immutep’s efti with radiotherapy and pembrolizumab meets primary endpoint in phase II trials for soft tissue sarcoma ...

“Plato is a liar,” says Flint Dibble, an archaeologist and Marie-Sklodowska Curie Research Fellow at Cardiff University.” He never claims to be writing history.” But though Plato’s ...

Paweł’s decision reflects a growing challenge in Poland’s labour market. An ageing population and historically low ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planne ...

CEO Marc Voigt delivers an update on the company’s recent clinical milestones, highlighting significant progress across multiple cancer indications. The focus of the presentation is the company’s ...

Efti combination demonstrates significant tumor response in sarcoma trial, exceeding expectations without chemotherapy.